About us

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

  • Merck

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Pfizer Eastern Europe

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Alcon

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Community Foundation

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

become our partner

Improving the lives of patients
by developing proprietary, innovative

Prof. med. Patrick Serruys, EMBA

Przewodniczący Rady Doradczej

Światowej sławy ekspert w dziedzinie kardiologii interwencyjnej i obrazowania medycznego z ponad czterdziestoletnim doświadczeniem w badaniach klinicznych. Jest współtwórcą pionierskich procedur interwencyjnych i stosowanych w nich innowacyjnych wyrobów medycznych, takich jak stenty metalowe (BMS), stenty elutujące leki (DES), stenty bioresorbowalne (BRS) czy zastawki implantowane przezskórnie (TAVI). Obecnie jest uznanym profesorem medycyny interwencyjnej i innowacji w National University of Galway (Irlandia) i honorowym profesorem kardiologii w NHLI, Imperial College in London.